肠道微炎症,通过粪便钙卫蛋白(FC)评估,被认为是功能性腹泻(FD)发病机理的组成部分。由于益生菌可以通过与有害细菌竞争来抑制肠道微炎症,我们假设它们可以减少FD患者的便便散症状和肠道炎症的比例.我们进行了双盲,安慰剂对照试验,以评估植物乳杆菌CJLP243在FC水平升高的FD患者中的临床和实验室效果两个月。24名诊断为FD且FC水平升高的患者被随机分配到益生菌组或安慰剂组。两个月后,益生菌组的10名患者和安慰剂组的12名患者完成了研究,和FD症状,FC值,在这些受试者中重新评估肠道菌群。与基线相比,两个月后,益生菌组中FD缓解(稀便频率降低)的受试者百分比显着增加。此外,与治疗前相比,益生菌组显示出对数转化FC值的统计学显着下降,而安慰剂组在干预前后没有差异。此外,研究结束后,与基线值相比,益生菌组肠道菌群组成中的明串珠菌属生物水平显著增加.在这个初步的探索性研究中,我们发现,两个月的植物乳杆菌CJLP243治疗导致FD症状改善,减小的FC值,并增加了明串珠菌的水平,表明摄入植物乳杆菌对这些患者有帮助。这些发现需要通过进一步的临床研究来验证。
Micro-inflammation in the gut, assessed by fecal calprotectin (FC), is considered a component of the pathogenesis of functional diarrhea (FD). Since probiotics may suppress micro-inflammation in the intestine by competing with harmful bacteria, we hypothesized that they would reduce the ratio of loose stool symptoms and gut inflammation in patients with FD. We conducted a double-blind, placebo-controlled
trial to assess the clinical and laboratory effects of Lactobacillus plantarum CJLP243 in FD patients with elevated FC levels for two months. Twenty-four patients diagnosed with FD with elevated FC levels were randomly assigned to either a probiotic group or a placebo group. After 2 months, 10 patients in the probiotic group and 12 patients in the placebo group completed the
study, and FD symptoms, FC values, and intestinal flora were re-evaluated in these subjects. The percentage of subjects who had adequate FD relief (decrease in loose stool frequency) in the probiotic group was significantly increased after two months compared with the baseline. In addition, the probiotic group showed a statistically significant decrease in log-transformed FC values compared with the pre-treatment group, whereas the placebo group showed no difference before and after the intervention. Furthermore, the levels of
Leuconostoc genus organisms in the gut microbiota composition in the probiotic group increased significantly after the end of the
study compared with the baseline values. In this preliminary exploratory research, we found that two months of Lactiplantibacillus plantarum CJLP243 treatment resulted in FD symptom improvement, reduced FC values, and increased
Leuconostoc levels, suggesting that the intake of Lactiplantibacillus plantarum was helpful in those patients. These findings need to be validated via further clinical studies.